Patents by Inventor Mark G. Bock

Mark G. Bock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5204349
    Abstract: Compounds of the formula: ##STR1## where R.sup.1 is hydrogen or hydroxy and R.sup.2 is a substituted amino group, a substituted heterocyclic ring or a substituted alkyl. These compounds are oxytocin and vasopressin antagonists useful in the treatment of preterm labor, dysmenorrhea and for the stoppage of labor preparatory to cesarean delivery, timing of parturition, uterine hyperactivity, endometriosis, hypertension, congestive heart failure, hyponatremia and cognitive disorders. Also disclosed are pharmaceutical compositions containing these compounds, methods of their use and methods of their preparation.
    Type: Grant
    Filed: September 16, 1991
    Date of Patent: April 20, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Mark G. Bock, Ben E. Evans, Roger M. Freidinger, Kevin Gilbert, Doug W. Hobbs, James B. Hoffman, George F. Lundell, Douglas J. Pettibone
  • Patent number: 5189050
    Abstract: Pharmaceutical compositions containing Virginiamycin M.sub.1 having the Formula: ##STR1## and Virginiamycin M.sub.1 analogs having the Formulae I-IV: ##STR2## are disclosed which are useful in the treatment of panic disorder or anxiety disorder.
    Type: Grant
    Filed: June 3, 1991
    Date of Patent: February 23, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Roger M. Freidinger, Mark G. Bock, Yiu-Kuen T. Lam, Raymond S. Chang, Otto D. Hensens, Cheryl D. Schwartz, Deborah L. Zink
  • Patent number: 5185331
    Abstract: Pharmaceutical compositions containing Triazolobenzodiazepines of the formula: ##STR1## are disclosed which are useful in the treatment of panic disorder or anxiety disorder.
    Type: Grant
    Filed: May 14, 1991
    Date of Patent: February 9, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Roger M. Freidinger, Mark G. Bock, Ben E. Evans
  • Patent number: 5177071
    Abstract: Pharmaceutical compositions containing 6-membered heterocyclic rings are disclosed which are useful in the treatment of panic disorder or anxiety disorder.
    Type: Grant
    Filed: June 17, 1991
    Date of Patent: January 5, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Roger M. Freidinger, Ben E. Evans, Mark G. Bock
  • Patent number: 5175159
    Abstract: Compounds of Formula I are antagonists of oxytocin and are useful in the treatment of preterm labor and dysmenorrhea, and for stoppage of labor prepatory to Caesarean delivery.
    Type: Grant
    Filed: December 28, 1990
    Date of Patent: December 29, 1992
    Assignee: Merck & Co., Inc.
    Inventors: Mark G. Bock, Ben E. Evans, Roger M. Freidinger
  • Patent number: 5166151
    Abstract: Aromatic 2-benzazepines with fused 5- or 6-membered heterocyclic rings which are antagonists of cholecystokinins and/or gastrin, and are useful in the treatment or prevention of CCK-related and/or gastrin-related disorders of the gastrointestinal, central nervous and appetite regulatory systems; compositions comprising these compounds; and methods of treatment of mammals or of increasing food intake of animals employing these compounds.
    Type: Grant
    Filed: March 11, 1991
    Date of Patent: November 24, 1992
    Assignee: Merck & Co., Inc.
    Inventors: Roger M. Freidinger, Ben E. Evans, Mark G. Bock
  • Patent number: 5026703
    Abstract: Peptide compounds of formula I are antagonists of oxytocin and are useful in the treatment of preterm labor and dysmenorrhea, and for the stoppage of labor prepatory to Caesarian delivery.
    Type: Grant
    Filed: June 11, 1990
    Date of Patent: June 25, 1991
    Assignee: Merck & Co., Inc.
    Inventors: Mark G. Bock, Roger M. Freidinger, Robert M. DiPardo
  • Patent number: 5004741
    Abstract: Methods of antagonizing gastrin and/or cholecystokinin (CCK) with benzodiazepine analogs are disclosed, as well as related pharmaceutical compositions, which are useful in treating disorders of the gastrointestinal tract, central nervous system, and of the appetite.
    Type: Grant
    Filed: November 9, 1988
    Date of Patent: April 2, 1991
    Assignee: Merck & Co., Inc.
    Inventors: Ben E. Evans, Mark G. Bock, Roger M. Freidinger
  • Patent number: 4847248
    Abstract: Aromatic 1,4-benzodiazepines with fused 5- or 6-membered heterocyclic rings which are antagonists of cholecystokinins and/or gastrin, and are useful in the treatment or prevention of CCK-related and/or gastrin-related disorders of the gastrointestinal, central nervous and appetite regulatory systems; compositions comprising these compounds; and methods of treatment employing these compounds.
    Type: Grant
    Filed: January 6, 1988
    Date of Patent: July 11, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Roger M. Freidinger, Ben E. Evans, Mark G. Bock
  • Patent number: 4820834
    Abstract: Benzodiazepine analogs of the formula: ##STR1## are disclosed which are antagonists of gastrin and cholecystokinin (CCK).
    Type: Grant
    Filed: March 16, 1987
    Date of Patent: April 11, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Ben E. Evans, Roger M. Freidinger, Mark G. Bock
  • Patent number: 4812442
    Abstract: Enzyme tripeptides of the formula: ##STR1## and analogs thereof which inhibit renin and are useful for treating various forms of renin-associated hypertension, hyperaldosteronism and congestive heart failure; compositions containing these renin-inhibitory peptides, optionally with other antihypertensive agents; and methods of treating hypertension, hyperaldosteronism or congestive heart failure or of establishing renin as a causative factor in these problems employing the novel tripeptides.
    Type: Grant
    Filed: May 4, 1987
    Date of Patent: March 14, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Joshua S. Boger, Ben E. Evans, Mark G. Bock
  • Patent number: 4755508
    Abstract: Benzodiazepines of the formula: ##STR1## are disclosed which are antagonists of gastrin and cholecystokinin (CCK).
    Type: Grant
    Filed: February 27, 1987
    Date of Patent: July 5, 1988
    Assignee: Merck & Co., Inc.
    Inventors: Mark G. Bock, Ben E. Evans, Roger M. Freidinger
  • Patent number: 4735941
    Abstract: Aromatic 1,4-benxodiazepines with fused 5- or 6-membered heterocyclic rings which are antagonists of cholecystokinins and/or gastrin, and are useful in the treatment or prevention of CCK-related and/or gastrin-related disorders of the gastrointestinal, central nervous and appetite regulatory systems; compositions comprising these compounds; and methods of treatment employing these compounds.
    Type: Grant
    Filed: December 23, 1986
    Date of Patent: April 5, 1988
    Assignee: Merck & Co., Inc.
    Inventors: Roger M. Freidinger, Mark G. Bock, Ben E. Evans
  • Patent number: 4724237
    Abstract: Novel 2-substituted-aminomethyl-1,4-benzodiazepines which have been found to be antagonists of the function of cholecystokinins (CCK), to the preparation of these compounds, and to the use of these compounds to antagonize the function of CCK, which antagonism is useful, e.g., for the treatment and prevention of disorders of the gastrointestinal, central nervous and appetite regulatory systems of mammals, especially of humans.
    Type: Grant
    Filed: June 26, 1984
    Date of Patent: February 9, 1988
    Assignee: Merck & Co., Inc.
    Inventors: Mark G. Bock, Roger M. Freidinger
  • Patent number: 4663321
    Abstract: Triazolobenzodiazepines of the formula: ##STR1## are disclosed which are antagonists of cholecystokinin (CCK).
    Type: Grant
    Filed: June 10, 1985
    Date of Patent: May 5, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Mark G. Bock, Ben E. Evans, Roger M. Freidinger
  • Patent number: 4663310
    Abstract: Renin inhibitory peptides of the formula ##STR1## and analogs thereof inhibit renin and are useful for treating various forms of renin-associated hypertension and hyperaldosteronism.
    Type: Grant
    Filed: April 4, 1984
    Date of Patent: May 5, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Mark G. Bock, Joshua S. Boger, Stephen F. Brady, Daniel F. Veber
  • Patent number: 4661473
    Abstract: Renin inhibitory peptides of the formula ##STR1## and analogs thereof inhibit renin and are useful for treating various forms of renin-associated hypertension and hyperaldosteronism.
    Type: Grant
    Filed: March 27, 1984
    Date of Patent: April 28, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Joshua S. Boger, Mark G. Bock
  • Patent number: 4636491
    Abstract: Renin inhibitory peptides of the formula ##STR1## and analogs thereof inhibit renin and are useful for treating various forms of renin-associated hypertension and hyperaldosteronism.
    Type: Grant
    Filed: March 27, 1984
    Date of Patent: January 13, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Mark G. Bock, Robert M. DiPardo, Joshua S. Boger, Ben E. Evans, Roger Freidinger
  • Patent number: 4628084
    Abstract: The present invention provides an improved process for producing 3-acylamino benzodiazepines of the formula: ##STR1## wherein: R is loweralkyl of from 1-6 carbon atoms, aryl such as phenyl and halophenyl, aralkyl, alkyloxy, aralkyloxy, indolyl or substituted indolyl;R' is hydrogen, loweralkyl of from 1-6 carbon atoms, carboxymethyl or carbalkoxymethyl wherein the alkoxy groups contain from 1-4 carbon atoms;X is hydrogen or halogen;Y is hydrogen or halogen.These compounds are useful because of their activity as cholecystokinin (CCK) inhibitors.
    Type: Grant
    Filed: January 2, 1986
    Date of Patent: December 9, 1986
    Assignee: Merck & Co., Inc.
    Inventors: Mark G. Bock, Daniel F. Veber, Robert M. DiPardo
  • Patent number: 4594191
    Abstract: A non-fermentation process for preparing a benzodiazepinedione of the formula: ##STR1## and intermediates is disclosed.
    Type: Grant
    Filed: April 22, 1985
    Date of Patent: June 10, 1986
    Assignee: Merck & Co., Inc.
    Inventors: Mark G. Bock, Ben E. Evans, Roger M. Freidinger, Steven M. Pitzenberger